| 000 | 01835 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516060811.0 | ||
| 264 | 0 | _c20120330 | |
| 008 | 201203s 0 0 eng d | ||
| 022 | _a2038-2529 | ||
| 024 | 7 |
_a10.1177/030089161109700411 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBantis, Athanasios | |
| 245 | 0 | 0 |
_aBisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies. _h[electronic resource] |
| 260 |
_bTumori _c |
||
| 300 |
_a479-83 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aBisphosphonate-Associated Osteonecrosis of the Jaw _xdiagnosis |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Neoplasms _xdiagnostic imaging |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMagnetic Resonance Imaging |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xpathology |
| 650 | 0 | 4 | _aRadionuclide Imaging |
| 650 | 0 | 4 | _aRadiopharmaceuticals |
| 650 | 0 | 4 | _aTechnetium Tc 99m Medronate |
| 650 | 0 | 4 | _aTomography, X-Ray Computed |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aZissimopoulos, Athanasios | |
| 700 | 1 | _aSountoulides, Petros | |
| 700 | 1 | _aKalaitzis, Christos | |
| 700 | 1 | _aGiannakopoulos, Stelios | |
| 700 | 1 | _aDeftereos, Savas | |
| 700 | 1 | _aTsakaldimis, Giorgos | |
| 700 | 1 | _aThomaidis, Vasilios | |
| 700 | 1 | _aTouloupidis, Stavros | |
| 773 | 0 |
_tTumori _gvol. 97 _gno. 4 _gp. 479-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/030089161109700411 _zAvailable from publisher's website |
| 999 |
_c21222840 _d21222840 |
||